Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PB018 Versus Ocrevus in Multiple Sclerosis
NCT07606521Phase 1Not yet recruiting
- Sponsor
- Polpharma Biologics
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial of PB018 in multiple sclerosis (MS) (3 arms), sponsored by Polpharma Biologics. Primary endpoint: Area under the concentration time curve. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
PB018
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07606521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07606521.